EDIT - Earnings call transcript Q4 2018

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Good afternoon, and welcome to Editas Medicine’s Fourth Quarter and Full-Year 2018 Conference Call. All participants are now in listen-only mode. There will be a question-and-answer session at the end of this call. Please be advised that this call is being recorded at the company’s request. I would now like to turn the call over to Mark Mullikin, Senior Director of Finance and Investor Relations at Editas Medicine. Sir?

Mark Mullikin

release afternoon, XXXX welcome the Q&A. the the conference we a approximately Good quarter prepared our and market fourth XXXX. for operator. two results issued the full-year financial and call. press quarter you, everyone, its After updates our to and fourth on hours we closed, and of Thank corporate our for providing Shortly Media will section call will be today’s after full-year & call of remarks, open replay available A Investors our website completion. after

differ XX-Q, Litigation is most remarks As by those various the section Act factors, a of forward-looking including a Risk constitute as quarterly results discussed recent with Actual reminder, this we indicated of various and report statements of future forward-looking important statements that Safe which company’s Factors Harbor result about in XXXX. expectations, on prospects Reform Form the plans, file of call those Securities the may the SEC. provisions purposes during our materially under for from make these Private the on

views be In as of not change. revise or views even addition, our our as statements date. if relied specifically any of only views upon obligation forward-looking representing should and any to update subsequent today, statements our We as any represent disclaim any forward-looking

Collins. will call Chief Now, Officer, over the turn Cindy our I to Executive

Cindy Collins

for and afternoon, the Good Mark. for thanks quarter everyone, us XXXX. fourth update our full-year Thanks, for joining corporate and call

Andrew President Corporate Albright, today Senior Myer, Officer; our Tim Financial executive to of including I’m Chief Hack, Charlie of our Vice Officer; Chief Vic joined our addition and members Scientific several our Hunt, Mark, Affairs. In Technology Officer; by Chief team,

in to exciting team first vivo anywhere we We translate juncture that the for the world. with working gene beyond. be to here our as are medicine clinic call, into Editas dedicated what who And durable of of the without enter patients’ today then human wouldn’t year review CRISPR past to in testing approved CRISPR the ahead we at we are over Medicine will look be editing of we an at the editors today’s promise XXXX and transform some On and medicines lives. achieved

for to our patients patients and trial X we Phase into EDIT-XXX So, give a These and of accomplishments cell to with culminating to value plan of collaboration momentum in Allergan. accomplishments and with patients partner patients the X, the mid-year for in half by employees. begin CRISPR history. favorable us shareholders create fortified for be We Hematology the additional screening American patent senior the We teams medicine sickle vivo our finally, best additions awarded to for let’s begin presentation CRISPR with trials the board key medicine organization our our our court our intellectual beta-thalassemia, with We alliances for deepened transformative in Allergan administered and issuances start and organizers. disease filings. providing an that and of strong expect to with a we permission we with medicine robust We LCAXX, at our base leadership FDA experimental just We and directors. strengthened runway few Celgene, advanced the in from capital lead many in clinical maintained with ASH expanded oral XXXX. received and the which medicines our of XXXX to and best-in-class EDIT-XXX potentially first initiate to dosing of December second was rulings property in when in Society and

medicines. expand establish to syndrome phase hire We our leadership and of transformative And to genomic we sickle development disease plan in clinical cell accelerate begin XA. and XXXX This late trials strategic experimental on Usher We best-in-class our stage next to lastly, IND year culture. pipeline growth. at have to of alliances to all at EMXX clinical expect expect for for platform least trials medicines us and to built executive enabling three for to of or positions outstanding activities and lead early stage ready this additional achieve goals least the our two in

Now, detail let Charlie the our discuss to Albright me in our progress call Chief to turn over Scientific Officer, pipeline more

Charlie Albright

be CRISPR you excited to in on Cindy. the you to Thanks all with today vivo well update both our programs. our Starting engineered as ocular our cell medicines, of I’m progress here as with medicine in portfolio.

partnership Leber in with We’re for Congenital Allergan. Amaurosis lead developing type EDIT-XXX experimental XX our medicine

the We’re the the is be quality first is even at as Much here The medicine nature CRISPR initial This medicine. Cindy examples patients notable pre-clinical vivo because more of summarized EDIT-XXX of IND review the we’re EDIT-XXX the upon science was EDIT-XXX for to in poised accepted was administered FDA for gratified in in world. of anywhere that acceptance manuscript in IND the November. that Editas. the recently work in and doing manuscript the tangible published are of the mentioned,

the interventional start dosing year We’re studies the half. second in patients the middle X by screening for Phase followed planning X, the in to of

We EDIT-XXX. expect the pediatric adult XX to this enroll and open label evaluate escalation and of safety dose to study in patients XX to efficacy

vision dose start dose more to efficacious will across a in We with but three up potentially five with levels We’ll severe loss. adults cohorts. low, test

will with We higher progress then of a doses broader vision. to adults range in

by be with an will pediatric a Following monitoring of range committee, safety data independent vision data patients included. review of

showed onset thereby forward growth editing it’s following the of expected dosing. CEPXXX worth to in trigger dosing months Productive within photoreceptors. nonhuman editing protein the and segments rapid As patients, outer few we a look is our in increase studies that recalling of preclinical primates and to mice a

ability and patients. New outer to to rescue segments should an in lead vision these hopefully light sense

natural potential identify In study. and side, the advance history natural points, key study the history study engage history we us for enable study natural sites. particular, conducting also examine we’re interventional a several As patients the interventional in can let EDIT-XXX, The ways. end

X/X sites The of seven will that have recruiting study anticipate across longer-term development we Phase the part study sites and instance, States this in clinical Europe. United of and We For program. be the these

expect to also Gene at USHXA. another the data and and in addresses retinal LCAXX, photoreceptors. Innovation Therapy called some Usher Like The We next collected Summit be program disease presented the type USHXA or inherited EDIT-XXX, Retinal Cell April. today the demographic affects XA Syndrome baseline

same reasons, these photoreceptors the same leverage CasX the For specific vector, we entire same the promoter. aureus from namely the and can construct product almost EDIT-XXX Staphylococcus AAV

medicine EDIT-XXX presented academic initial plan the believe and Cell the last Gene de-risk Society and and collaborators year Massachusetts these the Eye USHXA. data between We and expect in we and and at American guide accelerate that for from RNAs We USHXA present with therapy additional results will similarities development only of of experimental May. the difference be to therapy Ear our

uniquely develop Finally, approach is aureus pyogenes gene AAV, with editing us single large it’s we EDIT-XXX. worth too CasX to use with success medicines because to mentioning CasX positions Staph AAV with that our Streptococcus this enable

with transformational us in other that ocular with vivo serious we a in editing lead pipeline position our to from therapies. work progress therapeutic the ocular begin good In are eye work areas in to our learnings to were making addition, diseases, could help patients

possible. cell of Turning next the transformative medicines, convergence the of in to editing engineered are our is gene medicines cause medicines expanding in now cell programs that

serious diseases. number working in different a several types cell for are of We

cell that hemoglobin. to contrast, In results edit lineages edit our for may had development. increases at those sickle blood translate all If and yield within beta gene reduced humans, as more the and best-in-class the in editing of a with lower our program BCLXXA of edit other the At that a including editing and start medicines the locus than to that cell sites the globin found were in approach, to precursor locus Let’s medicine survive. others treat directly. gene cell globin precursors engineered an system, the showed American enhancer fetal editing our cells We cells increase of repopulated precursors. develop editing element levels red cells hemoglobin Society In we safer approach hemoglobinopathy thalassemia. preclinical of at BCLXXA and both red Hematology importantly indirectly medicine the fetal effective these enhancer meeting, cell we that blood blood

abstracts selected exciting cancer. initiate enabling we and our one will IND X,XXX, investing Our at exemplifying from this of on presentation we’re the program in medicines to the Switching as quality of gears ASH a over again science chosen of of to to field ASH data work best develop eleven year, Editas. engineered significantly additional was present this Later activities. in Oncology, cell treat

We are allogeneic approaches. and tumors solid advancing and liquid using both programs autologous address to

the killer with utilizing We cells. on have programs T in year. wholly-owned programs these More cells programs and engineered natural to come about Celgene later

discuss to over Now, our I’ll financial the review building to how are business call Officer, Hack and the to our Financial we Chief results. Andrew turn

Andrew Hack

year. exercised my financial and results It’s update in options to sustainable co-development the EDIT-XXX the each a pleasure developments in profit-sharing States. our and respective form XXXX, we’re our We progress strategic for over past Allergan, today. as we you Allergan part key made collaboration with In The XX-XX of strong to business partnership summarize and reporting the United Thanks a in and building valued on to Charlie. business

responsible CRISPR/CasX acceptance concerning regular million issued and in for As received a we commercialization royalty this circuit and intellectual for includes XXX XXXX EDIT-XXX pending single-digit Outside in a We and the federal Editas. of product validates exclusively from high to years the IND U.S. with for which on ahead. continues milestone expanding territories. $XX and ended and to a XX to sales U.S. were continues result court to and look strategic excellent ruling robust portfolio. our year the in them executing and of our net payments We patents U.S. Allergan. the our continued remains strategy a pattern of subsequent Allergan forward partner the property, that we trademark of of expand Allergan that over of applications believe offices’ and pleased and also milestones that to decision decision entitled over intellectual CRISPR/CpfX, EDIT-XXX, aggregate basis. on appeals we the our and success was foundational for patents licensed investment both development for interference be affirmed EDIT-XXX property the are those into an fortifying U.S., development

in available the the and we our numbers, release XXXX quarter for press XX-K hour that file to we we expect made to Turning fourth results ago shortly. an full-year summarized and financial our the have

increased December million marketable Our of cash, cash $XX December XX, equivalents to XXXX. $XXX million XXXX $XXX million securities as XX, from of XXXX in and as

and and million million $X stock-based of of associated of $XXX in million capital operating the and cash expenditures uses of capital. million and our items totaled $X include non-cash million $XX million. of R&D expenses working $XX with include recorded acquisition of a cash Key license non-cash $XX statement $X Our of million depreciation our in Pharmaceuticals; compensation, to from assets increase charges payments IX income

by size our Over in the in in to course drivers expect and organization to we drivers from maturing employees of the end the full-time of year, XXXX primary of our the platform, expanding increasing spending were to XXX advances XXXX. and pipeline The approximately XX% be primary XXX XXXX. growth we grew spending at of growth and of our continue in these our

of business We other Cindy. sources of and cash position believe And employee plan, our transformative from of it capital $XX back stock XX to million stock milestone purchase to of hand of million our I exercises, employees through million provides and million XXXX $XXX by Our the year-end multiple raise, purchase stock at totaled advancement of $XX development capital our million million our equity $X sources. fund in with cash and medicines. $XXX experimental of of that, least $XX option consisted various months payments from partners,

Cindy Collins

Thanks, Andrew.

Before up on next me prepared briefly transition our let to we phase of comments, our organizations growth. remark the wrap

and my changes the the we board with recent Dr. appointment Editas the just our team. and are CEO, departing Andrew We like have experimental and addition also us medicine. of And thank you the announced executive clinic our Bosley; their to CFO, I leadership strengthen for in as to Hack advancing midst David Katrine continued directors first building toward our with Scadden weeks of to know, ago. in would of

the clinical become as assistance company. executive We forward have active search leaders a with leading searches firms and appointing new positions for underway to of stage we outstanding look both

promise and enter We our have we to experimental CRISPR we first lives. technology medicine us the as exciting of expect clinic the of an transform patients’ ahead that with demonstrate year potential to

open and our your expect we to Q&A. up interest the thank of We the many support. be and we for you XXXX beyond. this first all call as of pipeline that, advance will With We in for

Operator

first Harrison you. Instructions] Morgan comes Matthew Stanley. Thank question [Operator Our from with

open. line Your is

Hannah Latimer

at I your was is companies? are other this allogeneic versus Hana are differentiating at some Thanks. your what features stage CRISPR what Matthew. for key approach programs just wondering in on Hi, and

Vic Myer

Chief Genome engineering So, high strategies ameliorate this We is recent Keystone efficiency Vic multi-gene editing did Technology and to disclose the Myer, recently translocations meeting. some Officer. at

We programs we're the haven't at this or of disclosed the indications specific going nature that after point.

Hannah Latimer

you. Thank Okay.

Operator

with next Our J.P. comes Morgan. question Cory from Kasimov

is line Your open.

Matthew Thomas

Hi, on for question. is This Matthew Cory. guys. Thanks for my taking

approach Just curious see of forward? and on how and killer interest role figure into cells, fitting oncology autologous the collab curious your on is [indiscernible] your health thoughts CAR in to your T natural you strategy high-level going

Charlie Albright

four cells. we’ve kind can effective tremendous collaboration autologous goes you milestones really of as I too a that appreciate tremendous on they we We question. are our be about in there. and about as technical natural excited has we’re different of more much killer area We to about our progress achieved our and efforts the will are much oncology hear you say, comment We the on. year the in What Celgene, really cell that part potential can’t with think That’s made there. a excited

Matthew Thomas

on when sickle both And cell your beta-globin in then and are what to therapy thoughts differentiators potential gene Okay, program, your great. disease? on beta-thal compared

Charlie Albright

really different comparison a isn’t And they there point. at Obviously, that approaches. approaches are this head-to-head

that is some I editing fetal gene the that to, what hemoglobin. in CRISPR advantages recreating – to human think have beta-globin make locus we’re that increase led and us mutations has which genetics has significant

And that trying recapitulate led. sense genetics we’re think in where has to so, I human

an that’s think to interesting way go. I

Matthew Thomas

my Thanks Great. questions. for taking

Operator

comes from The next Guggenheim. question Whitney with Ijem

is open. line Your

Whitney Ijem

Hi, the guys. Thanks question. for taking

if is some talk to if leverage just LCAXX you package between pre-clinical advance back Sorry and clinic between of more But to I the missed USHXA, synergies to circle there the can there the and to about this. wanted that just into ability programs, the wondering rapidly?

Charlie Albright

Charlie. those gene and quite virus. And editing serotype the we'll the this is same is promoter, There adeno-associated There within is therapeutic between so use are same be same tremendous going are synergies to further we’re guide both everything able approach the we the in deliver delivering that be tremendous except synergies, the two machinery the same RNAs. to and the receptors programs similar single a AAVX programs, – to because for will

but plays out or in we discovery with in clearly the that expect basis in much experience program the all the how constructed in be details the of with the the FDA, pharmacology rapidly the how the timeline we’ve and so, program. And we have don’t phase in more leverageable to LCAXX really we models we USHXA constructed know, package exactly USHXA safety done our program, without

Whitney Ijem

Thanks. Great.

Operator

& Our Cowen next question comes from Company. with Phil Nadeau

Your line is open.

Phil Nadeau

afternoon. Thanks Good my taking for questions.

the the has manufacturing, trial what clinical are clinical workstreams in the more several First talk and on the opening now Can are of you between bit take will the and there initiation the months? when about a detail what trial. little bottlenecks is that is first happen to screened, patients sides,

Vic Myer

the mentioned more. all doing and you just We’re things

approved. get IRB So, we got to the We Institutional approval IND Biosafety and Board have need approval.

screened get then to patients have get a of on eventually to site. have delivering for we to the procedure We them drug scheduled what’s the obviously the top surgical and

would trial you think disease just healthy same I rare where on you in stick these diseases turn or the can in way in the So, enrolling common that more can’t you volunteers. in appreciate a a you're

really actually the to a ability dose things it’s that up So, all the patient. go to

Phil Nadeau

for or do – that full manufacturing still is the or there in the dose happen? run drug therapy to a manufactured you And must the order manufactured trial have

Charlie Albright

we’ve runs. the well GMP IND development approved as aware, So, you’re as as several in I’m to have runs, compatible order to – had get sure

comfortable So, network. with process we're our and comfortable we’re with our

Phil Nadeau

Got it.

Okay.

a is may Second, part not go on control bigger be of or is out, your the there you provision Celgene subject or of that Celgene in any may even organization? unmodified collaboration, obviously collaboration if to change take does collaboration

Andrew Hack

No. it’s Phil, changes nature that the of the agreement. Andrew. of change There’s control Hi, no

So, is Celgene planned. not will the Celgene collaboration as has or acquired acquired continue

Phil Nadeau

other for congrats at Andrew question tenure on One you. it. Editas. financial your Got

Allergan over agreement? are milestones transaction, of the you are life the On in the remind how booked, amortized they us they can

Andrew Hack

the The is opt milestone in. than treated Yes. differently acceptance associated $XX milestone $XX the million IND with million

XX treated take more the deferred And to through gets in didn’t in gets so, as we contingent it detail, some and accounting of actually is time. added but pool the consideration that revenue over the brought

Phil Nadeau

it. Got

me from Okay. patent landscape. one on And that’s last then question the

patent there California issued, developments just over couple that University or next to forward on that perspectives are we that the second is what was patent the and of on should are patent months any First of look quarters? your

Andrew Hack

I’ll one The as well one that is was for thanks, the in interference. patents and of the that thanks the Phil, take involved patent allowed that congratulations. was recently

allowed to be with the it cleared. expect interference We having

think way of feel more medicines worth is good of also really much structured, CRISPR top I our the and constraints reading that under technology. This better. those understand covers from and we think all they it's in key have patent our about structure it’s the issuance UC, detailed this a this using any think IP. IP, some to those others I I details are worth is some noting covered clients affect constraints obviously which doesn't just guide patent, that And the RNA that’s horizon discussion, just think on but issuing

Phil Nadeau

very congrats my That's Thanks transition. helpful. and on it. taking again your for questions Got

Andrew Hack

Phil. Thanks,

Operator

with next Amanda BTIG. Our question Murphy comes from

line is open. Your

Amanda Murphy

for Good taking Thanks afternoon. Hi. questions. the

past presented T using Celgene, follow-up a some the on you’ve cell had editing CpfX. I think actually Just data around in

discussions on, going XXXX but in part of agreement And just yet? know a that extending about the terms kind beyond extending have the agreement I you and curious, also then had point this those discussions probably that have correct? is beyond you any lot or anything had So, at rates of have Celgene you of

Vic Myer

CpfX So, all genes fact CpfX reduces for comment discussions that Celgene. sort this of shown efficient We’ve for relationship editing is cells well the in translocations. We’ve an in combining I’ll the and with Vic. and and actually as shown shown Yes. the likely with the prolonging most multiplexing highly around the T-cells of of in primary genes CasX can't take we’ve question. CpfX nature on that allogeneic multiple package. frequency observed I of

Amanda Murphy

in you issued being is Okay seems got just enzymes, on else just anything seeing are like then if CRISPR that’s it. there on it advantages curious it CpfX And enzymes, patents be day every bring new as that to there or delivery out enzymes might system? interesting delivery clinical that’s ease you in-house has packaging whether your that or want – smaller new into

Vic Myer

Yes.

keep course literature are there’s on of an or on we new and So, molecules. eye lot the creating discovering people a working

so We’re really about and CasX can we the in happy of up feel really versions we They’re that them complementary with CasX. AAV All ways. and in both an many use. CpfX package We those. good

I have very think enzyme would to the bar for be high. new

or at two We’re XX% platforms. our better different editing with

Amanda Murphy

Okay. is that Kind theme. my This continuing last of question.

mean have technique single of a a of of able you have well. are to as unique might in lot AAV guide only structure to I use there you a obviously one delivery. little and be work strategy CpfX, bit you companies given the a obviously, or CRISPR And your then So, put maybe RNA into terms you of

those mentioned? I So, moving into interest pharma partners just if on you terms based maybe two curious in indications are other factors of from seeing

Vic Myer

Yes.

time we’re has to think So, molecules. and disclose of continue focus lot talking shown this interested the the the that for probably those I spend who are lot differentiates a there field, me again. speaking Vic there’s is of great and and inappropriate we things folks is in people lot with, a itself show of one of CasX a do is on to some we advantages it from that how I certainly it of have will CpfX but to mean,

Amanda Murphy

Got it. Thanks very much.

Operator

with Our next Gena Barclays. question Wang from comes

Your line is open.

Unidentified Analyst

Peter Hi, is Thanks taking questions. the for Gena. for this

courts of DSMD and is give long line? after happens will reviews dosing, How and or between of us color the what between And waiting cohort In terms between patients I terms within some of between any. And period in cohorts you have if in terms follow-up. a a be patients? could a there EDIT-XXX, time

Charlie Albright

there is the between be questions it Suffice haven’t Multiple say better. trials will very gene X/X that of will Phase Most to disclosed. and therapy other similar to be delay trial which a we be will small will happen times that an between safety head review, primarily but pediatric and cohort monitoring patients delay cohorts. data and At between independent patients. every will into not happen there to

the rest gene but by would you what’s of so be And timing from the therapy in happened surprised trials. – not

Unidentified Analyst

helpful. it. Got That’s

give place? terms type in when might visibility management any would any Thank that expect just that new organizational on any we changes decisions could color to what able your us or of discussions you changes, of to just be leaderships be Just you. strategic in into

Cindy Collins

This no Sure. direction strategic Cindy. in is have at change all. our And we

focus are I as my on company. the in EMXX our that overall on focused as comments and earlier We stated for to strategy continue guiding

comment In of such as to it’s on not CFO, as CEO, good just underway. the positions incredibly searches because is position. in, we other but terms strong company have feel uncertain, going searches of timing I again we very the and about too recruitment mentioned, I’m C-level

a lots the to We bank. leadership in the and into first have outstanding clinic, of team and cash go getting science ready

joining think candidates that really all they considering as about be would strong. Editas. Things So,

Unidentified Analyst

thank Great, you very much.

Operator

next Thank SunTrust [Operator from The Lawson comes question you. with Robinson. Peter Instructions]

open. is line Your

Peter Lawson

Thanks for taking my questions.

as we guess that I history think event? half – a still about Charlie, is the first Just natural

Charlie Albright

the things the for study. good We discussed into study. in will gating retinal have history study the study And at does start that prepared other the to interventional meeting for not us this natural important be presenting remarks. than idea we year, natural that a get also way of interventional baseline of part how history the other going any the hopefully, the data It’s that early in in is we realize

Peter Lawson

then the be Got will study? seen presented? And can what that how you. And be data

Charlie Albright

that begins study. can are of which events for rare quickly sites also and important we the should identify it it other and end state feat study challenges We’re dramatically might going, them us. grow of the one things. interventional these It does study, at those things gets interventional to but as in really possible. as potential potential patients improve of for the use up in the recruiting the is And looking couple both this points several a appreciate the interventional diseases as of the making in Whether you

Peter Lawson

then for And the that? we XXX, have we data or be what XXXX data kind timing should readouts that the could event when see of could around about think a we and and that should how

Charlie Albright

disclosed that. haven’t We

As you can imagine we are going to be monitoring the day in real-time.

We working are with that partner Allergan disseminate right to going our be way data. on to the to decide

you the between the to of real being As is can every how always the cautious release there release data notion appreciate trade-off about wanting of in piece data. time we in

we’re So, as interest about how data. the competing be see balancing we we will release so to think and when interpretation confident we those the

Peter Lawson

coming finally just out how that the IND on timing remind of studies know program, you then around program? relationship? the could on cancer any And And us you long left Juno is

Charlie Albright

of relationship and Celgene pretty that. XXXX the so partner now, till can’t ability a now is much disclose May can in programs too to of Celgene, with transitioned Juno, documents our has timing The unfortunately, the program disclosed Yes. large as as our pharma changed goes appreciate we dramatically and the as you say details to about

Peter Lawson

questions. Okay. taking Thank the you for much so

Charlie Albright

you. Thank

Operator

with Seedhouse comes next Raymond from Steve James. Our question

line open. Your is

Steve Seedhouse

Hi, best good new endeavor. in of your Andrew, afternoon. luck

actually editing the lower to interesting dose highest question pretty highest a of in EDIT-XXX mice a does month. of the rate had editing rate, so not study the it last that data result, Just that publication The in reasons dips about read preclinical below point so, I’m The to LCAXX dose. review that can curious in result? explanation to call, might peer are not leading that time. paper under just for on was you any at unclear Obviously, are reasons there that be we this that this are from

Andrew Hack

dose don’t beyond for why well and understand reason anticipate speculate is in dose that be could is it of didn’t the the humans. if paper No, that we kinds we reasons, which it in we result to all for realize the important different and using actually is

Steve Seedhouse

to of Okay. edits non-productive the of proportion depending CasX change or the The ratio concentration productive local on DNA? versus

Andrew Hack

not. No, I editing it dose profile independent. does think entire But is

Steve Seedhouse

the And know in you aggregate? if do can eye Okay. AAVX the capsids

Andrew Hack

that. the the do no programs know response virus will. to you AV once answer don’t we are you is to unloaded generate to do, an is very immunogenic you re-express the there's that if capsids No, capsid other and to we What transient way similar know the them because

Steve Seedhouse

Alright. you. Thank

Operator

you. this And time. I’m CEO for questions call any Cindy showing closing turn Thank Collins, now back to at like Ms. further to not I’d remarks. over the any

Cindy Collins

Great.

that, new work to we your to you Have for in we today’s bring as call So, with for and all support participating great medicines transformative thank patients. a evening.

Operator

day. Ladies and disconnect. may wonderful today’s have does conference. participating Everyone, This you you gentlemen, conclude for in a thank today’s program and all

Editas Medicine (EDIT) 28 Feb 192018 Q4 Earnings call transcript